

POSTER PRESENTATION

Open Access

# Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies

G Allais<sup>1\*</sup>, V Tullo<sup>2</sup>, S Omboni<sup>3</sup>, C Benedetto<sup>1</sup>, G Sances<sup>4</sup>, D Zava<sup>5</sup>, MD Ferrari<sup>6</sup>, G Bussone<sup>2</sup>

From The European Headache and Migraine Trust International Congress  
London, UK. 20-23 September 2012

## Objective

To review the efficacy and safety of frovatriptan (F) vs. rizatriptan (R), zolmitriptan (Z) and almotriptan (A), in women with menstrually related migraine (IHS criteria) through a pooled analysis of three individual studies.

## Methods

Subjects with a history of migraine with or without aura were randomized to F 2.5 mg or R 10 mg (study 1), F or Z 2.5 mg (study 2), and F or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design. After treating 3 episodes of migraine in no more than 3 months with the first treatment, patients had to switch to the next treatment for other 3 months.

## Results

346 subjects formed the main study intention-to-treat population; 280 of them were of a female gender (81%) and 236 in the fertile age. A total of 187 out of the 236 eligible women (79%) treated at least one episode of menstrual migraine with both medications and were thus included in the present subgroup analysis. Rate of pain free at 2, 4 and 24h was 23%, 52% and 67% with F and 30%, 61% and 66% with comparators ( $p=NS$ ). Pain relief episodes at 2, 4 and 24h were 37%, 60% and 66% for F and 43%, 55% and 61% for comparators ( $p=NS$ ). Rate of recurrence was significantly ( $p<0.05$ ) lower under F either at 24h (11% vs. 24% comparators) or at 48h (15% vs. 26% comparators). Number of menstrual migraine attacks associated with drug-related adverse events was equally low ( $p=NS$ ) between F (5%) and comparators (4%).

## Conclusions

According to our analysis of individual studies F is as effective as other triptans in the immediate treatment of menstrual migraine attacks, but exhibits a more sustained effect.

## Author details

<sup>1</sup>Department of Gynecology and Obstetrics, Women's Headache Center, University of Torino, Torino, Italy. <sup>2</sup>Department of Clinical Neurosciences, Carlo Besta National Neurological Institute, Milano, Italy. <sup>3</sup>Italian Institute of Telemedicine, Varese, Italy. <sup>4</sup>Headache Centre, IRCCS C. Mondino Foundation, Institute of Neurology, Pavia, Italy. <sup>5</sup>Istituto LusoFarmaco d'Italia, Milano, Italy. <sup>6</sup>Leiden Centre for Translational Neuroscience, Department of Neurology, Leiden University Medical Centre, Netherlands.

Published: 21 February 2013

## Reference

1. Savi L, et al.: *J Headache Pain* 2011, **12**:609-615, Allais G et al. *Neuro Sci* 2011;**32**(Suppl.1):S99-S104. Bartolini M et al. *J Headache Pain* 2012;in press.

doi:10.1186/1129-2377-14-S1-P191

Cite this article as: Allais et al.: Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies. *The Journal of Headache and Pain* 2013 **14**(Suppl 1):P191.

## Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)

<sup>1</sup>Department of Gynecology and Obstetrics, Women's Headache Center, University of Torino, Torino, Italy  
Full list of author information is available at the end of the article